A delayed clinical trial actually boosted Bristol Myers Squibb’s stock. Here’s why.

3 months ago 170

Bristol Myers’ stock rallied Wednesday as investors maintained high hopes for Cobenfy as an Alzheimer’s treatment, even though the outcome of a late-stage trial has been delayed.

Read Entire Article

A delayed clinical trial actually boosted Bristol Myers Squibb’s stock. Here’s why.

Related

Here are 7 charts guaranteed to stress you out about the sto...

More companies than usual are beating Wall Street’s expectat...

These ‘safer’ chip stocks have boomed this year. Is it too l...

Trending

Popular

More companies than usual are beating Wall Street’s expectat...

'Massive consolidation' expected across crypto industry: Bul...

Ethereum Foundation teams up with SEAL to combat wallet drai...

Jack Dorsey’s Block may cut up to 10% of staff in business o...

Bitcoin remains in tight range under $70,000 ahead of Wednes...

ETH taps $2.1K as crypto, macro markets rebound: Is the bott...

Memory-chip stocks are still quite cheap — especially if you...

Binance teams up with Franklin Templeton to use tokenized mo...

Here are 7 charts guaranteed to stress you out about the sto...

VCs clash over non-financial use cases in Web3 and crypto